Aptevo Therapeutics reports reduced infusion reactions for mipletamig in AML study
Aptevo Therapeutics announced that refinements to the priming‑dose regimen of its AML candidate mipletamig have substantially lowered infusion‑related reactions in the ongoing RAINIER study. The company said the improvement supports its discussions with the FDA and prepares the program for Phase 2 development in 2027. Results will be presented at the American Society of Hematology meeting in December 2026.
Why it matters
The company states the lower reaction rate enhances tolerability for frontline AML patients, which could facilitate FDA approval discussions and enable progression to Phase 2. Investors should note that the milestone may reduce clinical risk and keep the development timeline on track.
Key facts
- 1Successive refinements to mipletamig's priming‑dose regimen have substantially reduced infusion‑related reactions. stocktitan.net
- 2The RAINIER dose‑optimization study is expected to be completed by year‑end 2026. stocktitan.net
- 3Phase 2 development of mipletamig is planned for 2027. stocktitan.net
- 4Data will be presented at the American Society of Hematology 68th Annual Meeting in New Orleans from December 12‑15, 2026. stocktitan.net
- 5Mipletamig is being evaluated in combination with venetoclax and azacitidine in newly diagnosed AML patients unfit for intensive chemotherapy. stocktitan.net
- 6Dirk Huebner, M.D., Chief Medical Officer, said the reduced infusion reactions could make treatment easier to tolerate and limit care‑disrupting complications. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.